Grifols Announces Completion Of Follow-Up For All 345 Patients In Phase 3 SPARTA Trial Of Prolastin-C In Alpha-1 Emphysema; Topline Data Expected By End Of 2026
Share
Why It Matters
Grifols finished checking on all patients in a big test for a medicine that helps people with a lung disease called alpha-1 emphysema. They'll tell everyone the results by the end of 2026, so we'll know if the medicine really works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.